Search Results - "Keim, Ulrike"

Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036 by Garbe, Claus, Keim, Ulrike, Gandini, Sara, Amaral, Teresa, Katalinic, Alexander, Hollezcek, Bernd, Martus, Peter, Flatz, Lukas, Leiter, Ulrike, Whiteman, David

“…Cutaneous melanoma (CM) and keratinocyte cancer (KC) cause considerable morbidity and mortality. We analysed long-term trends of CM and KC in different white…”
Get full text

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial by Leiter, Ulrike, Dr, Stadler, Rudolf, MD, Mauch, Cornelia, Prof, Hohenberger, Werner, Prof, Brockmeyer, Norbert, Prof, Berking, Carola, Prof, Sunderkötter, Cord, Prof, Kaatz, Martin, MD, Schulte, Klaus-Werner, MD, Lehmann, Percy, MD, Vogt, Thomas, Prof, Ulrich, Jens, MD, Herbst, Rudolf, MD, Gehring, Wolfgang, MD, Simon, Jan-Christoph, Prof, Keim, Ulrike, PhD, Martus, Peter, Prof, Garbe, Claus, Prof

“…Summary Background Complete lymph node dissection is recommended in patients with positive sentinel lymph node biopsy results. To date, the effect of complete…”
Get full text

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study by Forschner, Andrea, Battke, Florian, Hadaschik, Dirk, Schulze, Martin, Weißgraeber, Stephanie, Han, Chung-Ting, Kopp, Maria, Frick, Maximilian, Klumpp, Bernhard, Tietze, Nicola, Amaral, Teresa, Martus, Peter, Sinnberg, Tobias, Eigentler, Thomas, Keim, Ulrike, Garbe, Claus, Döcker, Dennis, Biskup, Saskia

“…Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40-50% of…”
Get full text

Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany by Kramb, Felix, Doerfer, Christoph, Meiwes, Andreas, Ramakrishnan, Karthik, Eigentler, Thomas, Garbe, Claus, Keim, Ulrike, Leiter, Ulrike

“…Advanced cutaneous squamous cell carcinoma is a challenge to treat. Conventional systemic treatment options include chemotherapy and epidermal growth factor…”
Get full text

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients by Leiter, Ulrike, Loquai, Carmen, Reinhardt, Lydia, Rafei-Shamsabadi, David, Gutzmer, Ralf, Kaehler, Katharina, Heinzerling, Lucie, Hassel, Jessica C, Glutsch, Valerie, Sirokay, Judith, Schlecht, Nora, Rübben, Albert, Gambichler, Thilo, Schatton, Kerstin, Pfoehler, Claudia, Franklin, Cindy, Terheyden, Patrick, Haferkamp, Sebastian, Mohr, Peter, Bischof, Lena, Livingstone, Elisabeth, Zimmer, Lisa, Weichenthal, Michael, Schadendorf, Dirk, Meiwes, Andreas, Keim, Ulrike, Garbe, Claus, Becker, Jürgen Christian, Ugurel, Selma

“…BackgroundSkin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI)…”
Get full text

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy by Meckbach, Diana, Keim, Ulrike, Richter, Sabina, Leiter, Ulrike, Eigentler, Thomas K, Bauer, Jürgen, Pflugfelder, Annette, Büttner, Petra, Garbe, Claus, Weide, Benjamin

“…The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial. We analyzed the mutational status and overall…”
Get full text

Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma by Pflugfelder, Annette, Eigentler, Thomas K, Keim, Ulrike, Weide, Benjamin, Leiter, Ulrike, Ikenberg, Kristian, Berneburg, Mark, Garbe, Claus

“…Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Based on previous promising experiences within a clinical…”
Get full text

Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany by Leiter, Ulrike, Keim, Ulrike, Eigentler, Thomas, Katalinic, Alexander, Holleczek, Bernd, Martus, Peter, Garbe, Claus

“…Increasing incidence rates (IRs) of nonmelanoma skin cancer (NMSC) in white populations have been described worldwide. Cancer registry data from the Saarland…”
Get full text

Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland by Keim, Ulrike, Katalinic, Alexander, Holleczek, Bernd, Wakkee, Marlies, Garbe, Claus, Leiter, Ulrike

“…Cutaneous squamous cell carcinoma (cSCC) incidences are increasing but scarcely available separated. We analysed incidence rates of cSCC over three decades…”
Get full text

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node by Leiter, Ulrike, Stadler, Rudolf, Mauch, Cornelia, Hohenberger, Werner, Brockmeyer, Norbert H, Berking, Carola, Sunderkötter, Cord, Kaatz, Martin, Schatton, Kerstin, Lehmann, Percy, Vogt, Thomas, Ulrich, Jens, Herbst, Rudolf, Gehring, Wolfgang, Simon, Jan-Christoph, Keim, Ulrike, Verver, Danielle, Martus, Peter, Garbe, Claus

“…We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier:…”
Get full text

Cutaneous melanoma attributable to UVR exposure in Denmark and Germany by Keim, Ulrike, Gandini, Sara, Amaral, Teresa, Katalinic, Alexander, Holleczek, Bernd, Flatz, Lukas, Leiter, Ulrike, Whiteman, David, Garbe, Claus

“…Increasing incidence rates of cutaneous melanoma (CM) observed during the last five decades in white populations are largely attributed to increased exposure…”
Get full text

Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden by Satzger, Imke, Leiter, Ulrike, Gräger, Nikolai, Keim, Ulrike, Garbe, Claus, Gutzmer, Ralf

“…The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma…”
Get full text

Reporting of melanoma cell densities in the sentinel node refines outcome prediction by Ulmer, Anja, Pfefferle, Vanessa, Walter, Vincent, Granai, Massimo, Keim, Ulrike, Fend, Falko, Sulyok, Mihály, Bösmüller, Hans

“…Sentinel node biopsy is a key procedure to predict prognosis in melanoma. In a prospective study we compare reporting on melanoma cell densities in cytospin…”
Get full text

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma by Nanz, Lena, Keim, Ulrike, Katalinic, Alexander, Meyer, Thomas, Garbe, Claus, Leiter, Ulrike

“…Keratinocyte skin cancer, consisting of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is by far the most common cancer in white-skinned…”
Get full text

Prognosis in stage II melanoma of the head and neck depends on the histological subtype by Jasper, Sophie, Keim, Ulrike, Leiter, Ulrike, Amaral, Teresa, Flatz, Lukas, Forschner, Andrea

“…The melanoma guideline is mainly based on the AJCC stage. There is no difference according to histological subtypes such as superficial spreading melanoma…”
Get full text

Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR) by Forschner, Andrea, Eichner, Felizitas, Amaral, Teresa, Keim, Ulrike, Garbe, Claus, Eigentler, Thomas Kurt

“…Background During 2011 and 2014, new treatment modalities like tyrosine kinase inhibitors and checkpoint inhibitors were introduced into the therapy of…”
Get full text

Interim analysis of MelaRisk, a biomarker assay validation study in stage IB/IIA melanoma tissue by Forchhammer, Stephan, Chatziioannou, Eftychia, Sinnberg, Tobias, Niessner, Heike, Leiter, Ulrike M., Keim, Ulrike, Forschner, Andrea, Garbe, Claus, Flatz, Lukas, Amaral, Teresa Maria Santos

“…e21591 Background: Adjuvant therapy for melanoma patients (pts) is now available for pts from stage IIB onwards. Pts with cutaneous melanoma in early stages…”
Get full text

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts by Garbe, Claus, Keim, Ulrike, Suciu, Stefan, Amaral, Teresa, Eigentler, Thomas K, Gesierich, Anja, Hauschild, Axel, Heinzerling, Lucie, Kiecker, Felix, Schadendorf, Dirk, Stadler, Rudolf, Sunderkötter, Cord, Tüting, Thomas, Utikal, Jochen, Wollina, Uwe, Zouboulis, Christos C, Keilholz, Ulrich, Testori, Alessandro, Martus, Peter, Leiter, Ulrike, Eggermont, Alexander M M

“…Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This…”
Get full text

Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP) by Amaral, Teresa, Sinnberg, Tobias, Chatziioannou, Eftychia, Niessner, Heike, Leiter, Ulrike, Keim, Ulrike, Forschner, Andrea, Dwarkasing, Jvalini, Tjien-Fooh, Félicia, Wever, Renske, Flatz, Lukas, Eggermont, Alexander, Forchhammer, Stephan

“…Patients with cutaneous melanoma stage I/IIA disease are currently not eligible for adjuvant therapy, despite their risk for relapses and death. This study…”
Get full text

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment by Garbe, Claus, Keim, Ulrike, Amaral, Teresa, Berking, Carola, Eigentler, Thomas K, Flatz, Lukas, Gesierich, Anja, Leiter, Ulrike, Stadler, Rudolf, Sunderkötter, Cord, Tüting, Thomas, Utikal, Jochen, Wollina, Uwe, Zimmer, Lisa, Zouboulis, Christos C, Ascierto, Paolo A, Eggermont, Alexander M M, Grob, Jean-Jacques, Hauschild, Axel, Sekulovic, Lidija Kandolf, Long, Georgina V, Luke, Jason J, Michielin, Olivier, Peris, Ketty, Schadendorf, Dirk, Kirkwood, John M, Lorigan, Paul C

“…The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence…”
Get full text